硫胺素对脓毒性休克肾脏保护作用(TRPSS):一项随机安慰剂对照临床试验
TRPSS是一项多中心、随机、安慰剂对照试验,纳入88例脓毒性休克患者(硫胺素组42例,安慰剂组46例),评估硫胺素补充是否减轻肾损伤,主要终点为入组至入组后72小时血清肌酐变化。结果显示72小时肌酐组间差异无统计学意义(平均差-0.57 mg/dl,95%CI -1.18至0.04,P=0.07);肾脏替代治疗(14.3% vs 21.7%,P=0.34)、急性肾损伤(KDIGO 3期,54.7% vs 73.9%,P=0.07)及死亡率(35.7% vs 54.3%,P=0.14)均无差异。硫胺素组无ICU天数更多(中位22.5天 vs 0.0天,P<0.01)。在硫胺素缺乏亚组(27.4%)中,肾衰竭率(硫胺素组57.1% vs 安慰剂组81.5%)和院内死亡率(28.6% vs 68.8%)组间无差异。
要点
- 主要终点72小时血清肌酐变化无统计学显著差异:平均差-0.57 mg/dl(95%CI -1.18至0.04,P=0.07)。
- 肾脏替代治疗率硫胺素组14.3% vs 安慰剂组21.7%(P=0.34),KDIGO 3期急性肾损伤54.7% vs 73.9%(P=0.07),均无统计学显著差异。
- 死亡率硫胺素组35.7% vs 安慰剂组54.3%(P=0.14),无统计学显著差异。
- 硫胺素组无ICU天数中位22.5天(IQR 0.0-25.0)vs 安慰剂组0.0天(IQR 0.0-23.0),P<0.01。
- 硫胺素缺乏亚组(占27.4%)中,肾衰竭率57.1% vs 81.5%、院内死亡率28.6% vs 68.8%,组间无差异。
适用人群与场景
- 脓毒性休克患者,共纳入88例(硫胺素组42例,安慰剂组46例)。
处置流程与药物剂量
- 干预为硫胺素与安慰剂对照;原文未给出硫胺素的具体剂量、给药途径、频次或疗程。
研究设计与关键结果
- 多中心、随机、安慰剂对照试验,纳入88例脓毒性休克患者(硫胺素组42例,安慰剂组46例)。
- 主要终点72小时血清肌酐变化:平均差-0.57 mg/dl(95%CI -1.18至0.04,P=0.07),组间无统计学显著差异。
- 肾脏替代治疗率:硫胺素组14.3% vs 安慰剂组21.7%(P=0.34)。
- KDIGO 3期急性肾损伤发生率:硫胺素组54.7% vs 安慰剂组73.9%(P=0.07)。
- 死亡率:硫胺素组35.7% vs 安慰剂组54.3%(P=0.14)。
- 无ICU天数中位数:硫胺素组22.5天(IQR 0.0-25.0)vs 安慰剂组0.0天(IQR 0.0-23.0),P<0.01。
- 硫胺素缺乏亚组(27.4%):肾衰竭率硫胺素组57.1% vs 安慰剂组81.5%,院内死亡率28.6% vs 68.8%,组间无差异。
证据类型、等级与局限
- 证据类型:多中心、随机、安慰剂对照临床试验。
对床旁实践的改变
- 在脓毒性休克患者中,硫胺素补充未显著改善72小时肌酐变化这一主要终点,肾脏替代治疗、KDIGO 3期急性肾损伤及死亡率亦无显著差异;硫胺素组无ICU天数更多。
- 对硫胺素缺乏亚组(27.4%)的肾衰竭率和院内死亡率,原文报告组间无差异。
- 原文未据此给出推荐。
指南或共识出处
- 临床试验注册号:NCT03550794(www.clinicaltrials.gov)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Rationale: Kidney injury is common and associated with worse outcomes in patients with septic shock. Mitochondrial resuscitation with thiamine (vitamin B1) may attenuate septic kidney injury. Objectives: To assess whether thiamine supplementation attenuates kidney injury in septic shock. Methods: The TRPSS (Thiamine for Renal Protection in Septic Shock) trial was a multicenter, randomized, placebo-controlled trial of thiamine versus placebo in septic shock. The primary outcome was change in serum creatinine between enrollment and 72 hours after enrollment. Measurements and Main Results: Eighty-eight patients were enrolled (42 patients received the intervention, and 46 received placebo). There was no significant between-groups difference in creatinine at 72 hours (mean difference, -0.57 mg/dl; 95% confidence interval, -1.18, 0.04; P = 0.07). There was no difference in receipt of kidney replacement therapy (14.3% vs. 21.7%, P = 0.34), acute kidney injury (as defined by stage 3 of the Kidney Disease: Improving Global Outcomes acute kidney injury scale; 54.7% vs. 73.9%, P = 0.07), or mortality (35.7% vs. 54.3%, P = 0.14) between the thiamine and placebo groups. Patients who received thiamine had more ICU-free days (median [interquartile range]: 22.5 [0.0-25.0] vs. 0.0 [0.0-23.0], P < 0.01). In the thiamine-deficient cohort (27.4% of patients), there was no difference in rates of kidney failure (57.1% thiamine vs. 81.5% placebo) or in-hospital mortality (28.6% vs. 68.8%) between groups. Conclusions: In the TRPSS trial, there was no statistically significant difference in the primary outcome of change in creatinine over time. Patients who received thiamine had more ICU-free days, but there was no difference in other secondary outcomes. Clinical trial registered with www.clinicaltrials.gov (NCT03550794).
参考来源
- Moskowitz A, Berg KM, Grossestreuer AV, et al. Thiamine for Renal Protection in Septic Shock (TRPSS): A Randomized, Placebo-controlled, Clinical Trial. Am J Respir Crit Care Med. 2023. PMID: 37364280. doi:10.1164/rccm.202301-0034OC
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。